Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Clene Inc. (CLNN : NSDQ)
 
 • Company Description   
Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.10 Daily Weekly Monthly
20 Day Moving Average: 119,525 shares
Shares Outstanding: 63.26 (millions)
Market Capitalization: $132.84 (millions)
Beta: 0.37
52 Week High: $17.82
52 Week Low: $2.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.37% -25.08%
12 Week -31.82% -26.31%
Year To Date -48.78% -39.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6550 SOUTH MILLROCK DRIVE SUITE G50
-
SALT LAKE CITY,UT 84121
USA
ph: 801-676-9695
fax: -
ir@clene.com http://www.clene.com
 
 • General Corporate Information   
Officers
Robert Etherington - President; Chief Executive Officer and Director
David J. Matlin - Chairman
Morgan R. Brown - Chief Financial Officer
Jonathon T. Gay - Director
Shalom Jacobovitz - Director

Peer Information
Clene Inc. (CORR.)
Clene Inc. (RSPI)
Clene Inc. (CGXP)
Clene Inc. (BGEN)
Clene Inc. (GTBP)
Clene Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 185634102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 63.26
Most Recent Split Date: (:1)
Beta: 0.37
Market Capitalization: $132.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 65.85
Price/Cash Flow: -
Price / Sales: 246.00
EPS Growth
vs. Year Ago Period: -10.53%
vs. Previous Quarter: -10.53%
Sales Growth
vs. Year Ago Period: -85.92%
vs. Previous Quarter: -84.92%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -60.51
12/31/21 - -56.21
09/30/21 - -37.22
Current Ratio
03/31/22 - 7.77
12/31/21 - 9.06
09/30/21 - 13.54
Quick Ratio
03/31/22 - 7.76
12/31/21 - 9.05
09/30/21 - 13.53
Operating Margin
03/31/22 - -7,360.93
12/31/21 - -5,207.33
09/30/21 - -4,595.48
Net Margin
03/31/22 - 3,085.56
12/31/21 - -1,347.16
09/30/21 - -2,420.43
Pre-Tax Margin
03/31/22 - 3,019.63
12/31/21 - -1,406.36
09/30/21 - -2,385.53
Book Value
03/31/22 - 0.03
12/31/21 - 0.20
09/30/21 - 0.09
Inventory Turnover
03/31/22 - 1.06
12/31/21 - 2.36
09/30/21 - 5.12
Debt-to-Equity
03/31/22 - 9.64
12/31/21 - 1.52
09/30/21 - 4.09
Debt-to-Capital
03/31/22 - 90.60
12/31/21 - 60.36
09/30/21 - 80.34
 

Powered by Zacks Investment Research ©